Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide

被引:55
作者
Dhillon, J [1 ]
Dickinson, JM [1 ]
Sole, K [1 ]
Mitchison, DA [1 ]
机构
[1] ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0HS,ENGLAND
关键词
D O I
10.1128/AAC.40.3.552
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacies of rifampin-containing preventive regimens were measured in Cornell model mice in which an initially severe infection with Mycobacterium tuberculosis K37Rv was first treated for 7 weeks with 25 mg of isoniazid and 1,000 mg of pyrazinamide per kg of body weight in the diet and then with one of four test regimens given by daily oral gavage for 6 weeks, These regimens were 15 mg of rifampin per kg alone (R), rifampin plus 25 mg of isoniazid per kg (RH), rifampin plus 150 mg of pyrazinamide per kg (RZ), or rifampin plus isoniazid and pyrazinamide (RHZ), The interval between the rifampin gavage and the gavage with the other drugs ranged from 10 to 45 min, so that interference with rifampin absorption did not occur, Mice were sacrificed at 11 and 20 weeks after the termination of chemotherapy, with each killing being preceded by 3 weeks of high-dose dihydrocortisone treatment, Entire spleens and lungs were cultured, The proportions of mice,vith positive spleens at either killing time were 73% of 43 mice treated with R, 63% of 41 mice treated with RH, 65% of 43 mice treated with RZ, and 53% of 45 mice treated with RHZ, a just significant (P = 0.04) trend for fewer positive spleens with increasing numbers of drugs in the regimen, However, no trend was found in the corresponding proportions of mice with positive spleens or lungs, which were 81, 63, 65, and 71% for mice treated with R, RH, RZ, and RHZ, respectively, Thus, in the Cornell model, R alone, RH, RZ, and RHZ all had similar efficacies.
引用
收藏
页码:552 / 555
页数:4
相关论文
共 18 条
[1]   KINETICS OF RIFAMPICIN AND ISONIAZID ADMINISTERED ALONE AND IN COMBINATION TO NORMAL SUBJECTS AND PATIENTS WITH LIVER-DISEASE [J].
ACOCELLA, G ;
BONOLLO, L ;
TENCONI, LT ;
GARIMOLDI, M ;
MAINARDI, M ;
NICOLIS, FB .
GUT, 1972, 13 (01) :47-+
[2]  
[Anonymous], 1991, Am Rev Respir Dis, V143, P700
[3]   SERUM CONCENTRATION AND HALF-LIFE OF RIFAMPICIN AFTER SIMULTANEOUS ORAL-ADMINISTRATION OF AMINOSALICYLIC ACID OR ISONIAZID [J].
BOMAN, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1974, 7 (03) :217-225
[4]  
DICKINSON J, 1992, ANTIMICROB AGENTS CH, V36, P2066, DOI 10.1128/AAC.36.9.2066
[5]   BACTERICIDAL ACTIVITY OF STREPTOMYCIN, ISONIAZID, RIFAMPIN, ETHAMBUTOL, AND PYRAZINAMIDE ALONE AND IN COMBINATION AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
DICKINSON, JM ;
ABER, VR ;
MITCHISON, DA .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1977, 116 (04) :627-635
[6]   ANTAGONISM BETWEEN ISONIAZID AND THE COMBINATION PYRAZINAMIDE-RIFAMPIN AGAINST TUBERCULOSIS INFECTION IN MICE [J].
GROSSET, J ;
TRUFFOTPERNOT, C ;
LACROIX, C ;
JI, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :548-551
[7]   TURNING INTERMITTENT REGIMENS INTO DAILY REGIMENS USING BLISTER-PACKS - AN EXPLORATION IN MURINE TUBERCULOSIS [J].
GUY, A ;
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE AND LUNG DISEASE, 1993, 74 (05) :310-316
[8]  
HALSEY N, 1994, 10 INT C AIDS INT C
[9]   LESS IS MORE - SHORT-COURSE PREVENTIVE THERAPY OF TUBERCULOSIS [J].
ISEMAN, MD .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 140 (05) :1187-1187
[10]   PHARMACOKINETICS OF ANTITUBERCULOSIS DRUGS IN PATIENTS [J].
ISRAILI, ZH ;
ROGERS, CM ;
ELATTAR, H .
JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (01) :78-83